Back to News
Market Impact: 0.25
Hikma Pharmaceuticals PLC - Depositary Receipt Price Target Decreased by 17.53% to $51.72
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
The average one-year price target for Hikma Pharmaceuticals PLC’s depositary receipt was revised down 17.53% to $51.72 per share from $62.71. The prior estimate was dated February 23, 2026.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.35
Ticker Sentiment
HIK-0.40
More News
- Why is PagSeguro Digital stock plummeting 30% today?
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Carnage beneath the record high: How to find cheap stocks without the traps
- Buy Tesla ahead of potential SpaceX merger, says Barclays
- As AI becomes more fractured, one names stands out: AMD
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock